Daniel William Nelson

Daniel William Nelson

Auto-generated profile, based on publicly available information

Daniel William Nelson

Department of Surgery, William Beaumont Army Medical Center, El Paso, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
MEMatthew J. Eckert
Matthew J. Eckert
TWThomas M. Wertin
Thomas M. Wertin
STStuart D. Tyner
Stuart D. Tyner
DNDaniel W. Do Nelson
Daniel W. Do Nelson
SISeth Izenberg
Seth Izenberg
MMMatthew J. Martin
Matthew J. Martin
BACKGROUND Early administration of tranexamic acid (TXA) has been associated with a reduction in mortality and blood product requirements in severely injured adults. It has also shown significantly reduced blood loss and transfusion requirements in major elective pediatric surgery, but no published data have examined the use of TXA in pediatric trauma. METHODS This is a retrospective review of all pediatric trauma admissions to the North Atlantic Treaty Organization Role 3 hospital, Camp Bastion, Afghanistan, from 2008 to 2012. Univariate and logistic regression analyses of all patients and select subgroups were performed to identify factors associated with TXA use and mortality. Standard adult dosing of TXA was used in all patients. RESULTS There were 766 injured patients 18 years or younger (mean [SD] age, 11 [5] years; 88% male; 73% penetrating injury; mean [SD], Injury Severity Score [ISS], 10 [9]; mean [SD] Glasgow Coma Scale [GCS] score, 12 [4]). Of these patients, 35% required transfusion in the first 24 hours, 10% received massive transfusion, and 76% required surgery. Overall mortality was 9%. Of the 766 patients, 66 (9%) received TXA. The only independent predictors of TXA use were severe abdominal or extremity injury (Abbreviated Injury Scale [AIS] score ≥ 3) and a base deficit of greater than 5 (all p < 0.05). Patients who received TXA had greater injury severity, hypotension, acidosis, and coagulopathy versus the patients in the no-TXA group. After correction for demographics, injury type and severity, vitals, and laboratory parameters, TXA use was independently associated with decreased mortality among all patients (odds ratio, 0.3; p = 0.03) and showed similar trends for subgroups of severely injured (ISS > 15) and transfused patients. There was no significant difference in thromboembolic complications or other cardiovascular events. Propensity analysis confirmed the TXA-associated survival advantage and suggested significant improvements in discharge neurologic status as well as decreased ventilator dependence. CONCLUSION TXA was used in approximately 10% of pediatric combat trauma patients, typically in the setting of severe abdominal or extremity trauma and metabolic acidosis. TXA administration was independently associated with decreased mortality. There were no adverse safety- or medication-related complications identified. LEVEL OF EVIDENCE Therapeutic study, level IV.

1 September 2012 in Archives of Surgery
Verified
Journal Article
Closed access
PDF file
DNDaniel W. Nelson
Daniel W. Nelson
KBKelly S. Blair
Kelly S. Blair
MMMatthew J. Martin
Matthew J. Martin
Research from JAMA Surgery — Analysis of Obesity-Related Outcomes and Bariatric Failure Rates With the Duodenal Switch vs Gastric Bypass for Morbid Obesity

1 August 2015 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
DNDaniel W. Nelson
Daniel W. Nelson
VSVlad V. Simianu
Vlad V. Simianu
ABAmir L. Bastawrous
Amir L. Bastawrous
RBRichard P. Billingham
Richard P. Billingham
AFAlessandro Fichera
Alessandro Fichera
SSScott R Steele
Scott R Steele
Venous thromboembolism (VTE) prevention in hospitalized patients has been promoted as a patient safety priority by a multitude of agencies.1 Despite the fact that colorectal surgery is one of the most commonly performed procedures, the American College of Chest Physicians’ revised evidence-based guidelines regarding strategies to reduce VTE among hospitalized surgical patients do not offer comprehensive recommendations for patients undergoing colorectal surgery.2,3 General strategies recommended in the American College of Chest Physicians’ guidelines regarding abdominal surgery, as well as the American Society of Clinical Oncology’s guidelines for VTE prevention in cancer,4 may be extrapolated and applied to patients with colorectal cancer. However, these patients represent a diverse population with an array of patient-related and procedure-associated factors that place them at particularly high risk of VTE. Quiz Ref ID Colorectal surgery is often performed for inflammatory disease or malignancy, which are known risk factors for VTE.5-8 In addition, lithotomy positioning, prolonged operative times, and pelvic dissection are procedure-specific risk factors associated with VTE.9 Quiz Ref ID In the absence of appropriate prophylaxis, rates of radiologically and clinically diagnosed VTE, including deep vein thrombosis (DVT) and pulmonary embolism, have been as high as 40% and 5%, respectively, following colorectal surgery.9 Among patients undergoing colorectal procedures who receive guideline-recommended chemoprophylaxis, VTE rates are as high as 9.4%.10 Furthermore, VTE risk peaks approximately 3 weeks after surgery and remains increased up to 12 weeks following surgery11 when most patients have already left the hospital. These data have been the impetus for exploring potential benefits of extended prophylaxis regimens.12,13

1 January 2014 in Journal of Cancer
Verified
Journal Article
Open access
EMElizabeth McKeown
Elizabeth McKeown
DNDaniel W. Nelson
Daniel W. Nelson
EJEric K. Johnson
Eric K. Johnson
JMJustin A. Maykel
Justin A. Maykel
ASAlexander Stojadinovic
Alexander Stojadinovic
SSScott R. Steele
Scott R. Steele
Introduction: With the advent of multidisciplinary and multimodality approaches to the management of colorectal cancer patients, there is an increasing need to define how we monitor response to novel therapies in these patients. Several factors ranging from the type of therapy used to the intrinsic biology of the tumor play a role in tumor response. All of these can aid in determining the ideal course of treatment, and may fluctuate over time, pending down-staging or progression of disease. Therefore, monitoring how disease responds to therapy requires standardization in order to ultimately optimize patient outcomes. Unfortunately, how best to do this remains a topic of debate among oncologists, pathologists, and colorectal surgeons. There may not be one single best approach. The goal of the present article is to shed some light on current approaches and challenges to monitoring treatment response for colorectal cancer.

1 May 2013 in The American Journal of Surgery
Verified
Journal Article
Closed access
DNDaniel W. Nelson
Daniel W. Nelson
TBTerin H. Blanchard
Terin H. Blanchard
MCMarlin W. Causey
Marlin W. Causey
JHJoseph F. Homann
Joseph F. Homann
TBTommy A. Brown
Tommy A. Brown

22 May 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
ADAhmed N. Dehal
Ahmed N. Dehal
AGAmanda N. Graff-Baker
Amanda N. Graff-Baker
BVBrooke Vuong
Brooke Vuong
DNDaniel Nelson
Daniel Nelson
SCShu-Ching Chang
Shu-Ching Chang
ABAnton J. Bilchik
Anton J. Bilchik